OTC$AIM
AIM ImmunoTech Inc · Q1 2026 earnings
Q1 2026 earnings · · Investor relations
Briefing
AIM ImmunoTech Inc reported Q1 2026 results with a narrowed net loss driven by lower operating expenses and equity financings.
The company recorded $22,000 in clinical treatment revenues and a net loss of $3.0 million for the quarter ended March 31, 2026, compared to a $3.7 million loss in the prior-year quarter. Operating expenses declined 38% year-over-year to $2.2 million, primarily from reduced R&D and G&A spending. Cash and cash equivalents rose to $5.8 million following multiple equity raises and warrant exercises.
- Net loss narrowed to $3.0 million from $3.7 million in Q1 2025 due to 38% lower operating expenses
- R&D expenses fell to $482,000 while G&A expenses declined to $1.8 million
- Cash position strengthened to $5.8 million through $5.6 million in financing activities
- Stockholders' equity improved to $2.1 million following rights offering and warrant exercises
Headline financials
Revenue & EPS history
AIM ImmunoTech · Revenue · Quarterly
$22K
Forward guidance
No explicit forward guidance provided in the filing.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2026
+20.2%
Avg return
Earnings day
-3.9%
Avg return
5 days after
-10.3%
Avg return
30 days after
50%
30 / 60 earnings
Positive
+946.2%
Q3 2011
Best reaction
-18.8%
Q4 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -3.8% | — | — | |
| Q4 2025 | -18.8% | -30.6% | -38.8% | |
| Q3 2025 | -7.6% | -4.9% | -5.6% | |
| Q2 2025 | +3.1% | -3.5% | +1.2% | |
| Q1 2025 | +0.0% | +0.0% | -25.6% | |
| Q4 2024 | +2.2% | -25.0% | -33.3% | |
| Q3 2024 | -8.8% | -20.0% | -12.0% | |
| Q2 2024 | +7.4% | +14.8% | +11.1% | |
| Q1 2024 | +0.9% | +2.5% | +12.5% | |
| Q4 2023 | -2.8% | +0.0% | -18.4% | |
| Q3 2023 | +7.3% | +2.3% | +20.5% | |
| Q2 2023 | -9.3% | -10.1% | -7.2% | |
| Q1 2023 | -3.5% | +6.8% | +4.5% | |
| Q4 2022 | +3.6% | +0.0% | +11.6% | |
| Q3 2022 | +1.0% | +0.0% | -27.1% | |
| Q2 2022 | -3.8% | -7.8% | -16.9% | |
| Q1 2022 | +2.4% | -7.3% | -8.3% | |
| Q4 2021 | -1.9% | +1.9% | -2.8% | |
| Q3 2021 | -7.0% | -14.6% | -35.1% | |
| Q2 2021 | -2.5% | -3.0% | -2.5% | |
| Q1 2021 | +3.0% | +5.0% | -98.9% | |
| Q4 2020 | +11.7% | +8.9% | +0.9% | |
| Q3 2020 | +6.3% | +3.7% | -3.7% | |
| Q2 2020 | +0.4% | -5.9% | -22.7% | |
| Q1 2020 | +8.9% | +4.7% | +10.2% | |
| Q4 2019 | +9.8% | +2.6% | -21.8% | |
| Q3 2019 | -5.6% | -8.2% | -8.2% | |
| Q2 2019 | +2.2% | +3.8% | +1.1% | |
| Q1 2019 | -6.7% | -13.3% | -23.0% | |
| Q4 2018 | +0.0% | -6.2% | +31.3% | |
| Q3 2018 | +0.0% | -9.1% | -13.6% | |
| Q2 2018 | -6.7% | -13.3% | -23.3% | |
| Q1 2018 | +0.0% | +3.3% | +0.0% | |
| Q4 2017 | +12.5% | +2.5% | -20.0% | |
| Q3 2017 | +0.0% | +0.0% | -3.1% | |
| Q2 2017 | +0.0% | -2.4% | -22.0% | |
| Q1 2017 | -6.3% | -17.2% | -18.8% | |
| Q4 2016 | +5.7% | +0.0% | +26.4% | |
| Q3 2016 | -2.2% | -9.9% | -11.0% | |
| Q1 2016 | +9.1% | — | — | |
| Q4 2015 | +8.3% | — | — | |
| Q3 2015 | +7.1% | — | — | |
| Q2 2015 | +0.0% | — | — | |
| Q1 2015 | -7.4% | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | +0.0% | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | -4.9% | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | -7.7% | — | — | |
| Q1 2013 | +0.3% | — | — | |
| Q4 2012 | +1.9% | — | — | |
| Q3 2012 | +281.0% | — | — | |
| Q2 2012 | +0.5% | — | — | |
| Q1 2012 | -1.9% | — | — | |
| Q4 2011 | +1.9% | — | — | |
| Q3 2011 | +946.2% | — | — | |
| Q2 2011 | -13.4% | — | — | |
| Q1 2011 | +2.4% | — | — | |
| Q4 2010 | -6.3% | — | — | |
| Q3 2010 | +1.3% | — | — | |
| Q2 2010 | +0.6% | — | — | |
| Q1 2010 | +3.5% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro